source
- GSK prepares for patent cliff with $2.5B cost-cutting planThe pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss of patents important to its HIV drug franchise.
- Boston Scientific unveils major restructuring, plots job cuts amid savings driveMedical device maker Boston Scientific has been a prolific dealmaker this year but is now taking a step back as it looks to make changes internally.